Recombineering with Red/ET will allow cloning, subcloning, and modification of DNA at any chosen position. It permits precise engineering of DNA molecules of any size, including large one
Also, CTI was ordered to immediately pay an additional $776,454 to Spectrum by wire transfer. Raj Shrotriya, MD, Chairman, CEO and President of Spectrum Pharmaceuticals, said: “we are
Presently, researchers use DNA sequencing as a method for identifying genetic variation. Scientists participating in an early evaluation of the technology are interested in studying the most widely
Claes Glassell, President and CEO of Cerus, said: “we are pleased to broaden and further strengthen our relationship with Grifols, one of the largest pharmaceutical companies in Spain
Ventilation care challenges such as treating respiratory failure from exacerbations of chronic obstructive pulmonary disease (COPD) while avoiding ventilator-associated pneumonia. Respironics V60 Ventilator This product provides traditional invasive
The trial (Freedom-301), a multi-center, randomized, double-blind, placebo-controlled Phase 3 trial designed to evaluate the safety and efficacy of Levadex as a potential treatment for acute migraine. Primary
The trial was a double-blind, randomized, active comparator study of LT-NS001 (formerly MX-1094) vs. naproxen in patients aged 45 to 70 years. In the trial, the patients underwent
Besides Congress, AdvaMed lobbied the Department of Health and Human Services and the FDA in the January-March 2009 period, according to a form filed April 20, 2009 with
“With MOSAIQ, Elekta brings proton therapy and radiation oncology expertise,” says Niek Schreuder, senior vice president of medical physics and technology at ProCure. “More importantly, Elekta shares ProCure’s
Cytokinetics will receive $50 million, and is expected to receive up to $600 million in future payments depending on the success of the drug, reported Reuters. Amgen has
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.